Medical Doctor Program year 2024 Reported 2019–2024 Source: CMS Open Payments, 2026 publication

Steven Freedman

Neurology Raleigh, NC Medical Doctor

NPI 1609891613 CMS profile 73377

1540 Sunday Dr, Raleigh, NC 27607

Open in the dashboard

General payments

$42,299

308 records reported · program years 2019–2024

Research payments

$0

Paid to them · None reported · program years 2019–2024

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$156,068 paid to institutions, not to them · program years 2019–2021

Through program year 2024, Steven Freedman of Raleigh, NC is reported in the CMS Open Payments database as having received $42,299 across 308 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $156,068 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 89th percentile of Neurology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2024 General $64 2
2022 General $118 3
2021 General $1,675 4
2020 General $180 7
2019 General $40,262 292

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Steven Freedman
  • Neurology median
  • Middle half of Neurology
  • National median

In program year 2025, general payments to Steven Freedman were reported at $0. Among 11,022 Neurology profiles paid that year, the median was $457 and the middle half received between $118 and $2,344.

Show as a table
Year Steven Freedman Neurology median Middle half National median
2019 $40,262 $474 $118–$2,177 $163
2020 $180 $367 $82–$2,309 $114
2021 $1,675 $438 $104–$2,547 $132
2022 $118 $442 $103–$2,388 $149
2023 $0 $464 $119–$2,312 $160
2024 $64 $468 $119–$2,323 $164
2025 $0 $457 $118–$2,344 $169

Breakdown

Who paid General payments · program years 2019–2024
  1. Genzyme Corporation $14,442 27 payments
  2. Biogen, Inc. $9,534 36 payments
  3. Alexion Pharmaceuticals, Inc. $4,807 13 payments
  4. Mallinckrodt Enterprises LLC $4,126 10 payments
  5. Teva Pharmaceuticals USA, Inc. $3,627 25 payments
  6. Genentech USA, Inc. $3,447 40 payments
  7. Novartis Pharmaceuticals Corporation $1,097 32 payments
  8. EMD Serono, Inc. $343 22 payments
  9. Supernus Pharmaceuticals, Inc. $227 67 payments
  10. Amgen Inc. $184 8 payments
  11. Other $464 28 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2024
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $20,547 9 payments
  2. Consulting Fee $11,850 7 payments
  3. Travel and Lodging $5,572 22 payments
  4. Food and Beverage $4,246 268 payments
  5. Education $85 2 payments
Products named General payments · program years 2019–2024
  1. AUBAGIO Multiple Sclerosis $8,788 18 payments
  2. ACTHAR $4,126 10 payments
  3. TECFIDERA $4,074 18 payments
  4. TYSABRI $4,008 11 payments
  5. PLEGRIDY $3,756 4 payments
  6. COPAXONE $3,453 2 payments
  7. OCREVUS $3,447 40 payments
  8. LEMTRADA $2,980 10 payments
  9. AUBAGIO Neurology $2,818 1 payment
  10. AIMOVIG $353 21 payments
  11. Other $1,975 161 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

308 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Neurology in North Carolina

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2024

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record